2026-526106-32-00Not yet recruitingPhase 1
[¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Sept 2026
Brief summary (registry, in English)
To quantify [¹⁸F]MC225 tracer kinetics as a measure of P-glycoprotein function at the blood–brain barrier in tumor and peritumoral regions of patients with radiological suspicion of glioblastoma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 18 Jun 2026
- Start date
- 2 Nov 2026
- Lead sponsor
- Universitair Medisch Centrum Groningen
- Diseases
- Glioblastoma
- EU CT number
- 2026-526106-32-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are thought, from scans, to have glioblastoma and will have surgery to reduce the tumor. It studies how the blood–brain barrier works using a PET scan.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Suspected glioblastoma on scans, mostly on one side of the brain, with surgery planned to reduce the tumor
- Earlier treatment
- Cannot be taking medicines that strongly affect P-glycoprotein function, unless they can be safely stopped before imaging
Main reasons for not taking part
- Cannot safely have PET or MRI, blood vessel catheters or gadolinium contrast
- Pregnant or breastfeeding
- Cannot give informed consent
- Brain or mental health conditions that could affect the study, in the investigator's view
- Tumor on both sides of the brain that prevents regional analysis
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications known to significantly affect P-glycoprotein function, unless these can be safely discontinued prior to imaging.
Other illness
- Contraindications to study procedures, including PET and MRI imaging, arterial or venous catheterisation, MRI, or administration of gadolinium-based contrast agents (e.g., non-MRI-compatible implants, severe contrast allergy, or impaired renal function).
- Relevant neurological or psychiatric conditions that may interfere with study participation, imaging quality, or interpretation of results, at the discretion of the investigator.
Other
- Pregnancy or breastfeeding.
- Inability to provide informed consent.
- Extensive bilateral tumor involvement precluding regional analysis.
Who the study is looking for
- Age 18 years or older.
- Radiological suspicion of glioblastoma.
- Candidate for tumor reductive surgery.
- Predominantly unilateral tumor suitable for regional imaging analysis.
- Eligible for contrast-enhanced MRI according to routine clinical safety screening.
- Able to undergo PET imaging, arterial and venous blood sampling according to the study protocol.
- Able to understand study information and provide written informed consent.
- Imaging procedures can be performed within 14 days prior to surgery without delaying standard clinical care
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UMCG | Groningen | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.